Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Yu Tzu Tai, Betty Y. Chang, Sun Young Kong, Mariateresa Fulciniti, Guang Yang, Yolanda Calle, Yiguo Hu, Jianhong Lin, Jian Jun Zhao, Antonia Cagnetta, Michele Cea, Michael A. Sellitto, Mike Y. Zhong, Qiuju Wang, Chirag Acharya, Daniel R. Carrasco, Joseph J. Buggy, Laurence Elias, Steven P. Treon, William MatsuiPaul Richardson, Nikhil C. Munshi, Kenneth C. Anderson

Research output: Contribution to journalArticle

Abstract

Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma (MM) growth within the BM microenvironment. PCI-32765 blocked RANKL/M-CSF - induced phosphorylation of Btk and downstream PLC-γ2 in OCs, resulting in diminished TRAP5b (ED50 = 17nM) and bone resorption activity. PCI-32765 also inhibited secretion of multiple cytokines and chemokines from OC and BM stromal cell cultures from both normal donors (ED50 = 0.5nM) and MM patients. It decreased SDF-1 - induced migration of MM cells, and down-regulated MIP1-α/CCL3 in MM cells. It also blocked MM cell growth and survival triggered by IL-6 or coculture with BM stromal cells or OCs in vitro. Importantly, PCI-32765 treatment significantly inhibits in vivo MM cell growth (P <.03) and MM cell-induced osteolysis of implanted human bone chips in SCID mice. Moreover, PCI-32765 prevents in vitro colony formation by stemlike cells from MM patients. Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM.

Original languageEnglish
Pages (from-to)1877-1887
Number of pages11
JournalBlood
Volume120
Issue number9
DOIs
Publication statusPublished - Aug 30 2012

Fingerprint

Multiple Myeloma
Tumors
Bone
Bone Marrow
Osteoclasts
Neoplasms
Cell growth
Therapeutics
Osteolysis
Stromal Cells
Growth
Phosphorylation
Macrophage Colony-Stimulating Factor
Osteogenesis
Programmable logic controllers
Chemokines
Cell culture
Agammaglobulinaemia tyrosine kinase
PCI 32765
Interleukin-6

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Tai, Y. T., Chang, B. Y., Kong, S. Y., Fulciniti, M., Yang, G., Calle, Y., ... Anderson, K. C. (2012). Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood, 120(9), 1877-1887. https://doi.org/10.1182/blood-2011-12-396853

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. / Tai, Yu Tzu; Chang, Betty Y.; Kong, Sun Young; Fulciniti, Mariateresa; Yang, Guang; Calle, Yolanda; Hu, Yiguo; Lin, Jianhong; Zhao, Jian Jun; Cagnetta, Antonia; Cea, Michele; Sellitto, Michael A.; Zhong, Mike Y.; Wang, Qiuju; Acharya, Chirag; Carrasco, Daniel R.; Buggy, Joseph J.; Elias, Laurence; Treon, Steven P.; Matsui, William; Richardson, Paul; Munshi, Nikhil C.; Anderson, Kenneth C.

In: Blood, Vol. 120, No. 9, 30.08.2012, p. 1877-1887.

Research output: Contribution to journalArticle

Tai, YT, Chang, BY, Kong, SY, Fulciniti, M, Yang, G, Calle, Y, Hu, Y, Lin, J, Zhao, JJ, Cagnetta, A, Cea, M, Sellitto, MA, Zhong, MY, Wang, Q, Acharya, C, Carrasco, DR, Buggy, JJ, Elias, L, Treon, SP, Matsui, W, Richardson, P, Munshi, NC & Anderson, KC 2012, 'Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma', Blood, vol. 120, no. 9, pp. 1877-1887. https://doi.org/10.1182/blood-2011-12-396853
Tai, Yu Tzu ; Chang, Betty Y. ; Kong, Sun Young ; Fulciniti, Mariateresa ; Yang, Guang ; Calle, Yolanda ; Hu, Yiguo ; Lin, Jianhong ; Zhao, Jian Jun ; Cagnetta, Antonia ; Cea, Michele ; Sellitto, Michael A. ; Zhong, Mike Y. ; Wang, Qiuju ; Acharya, Chirag ; Carrasco, Daniel R. ; Buggy, Joseph J. ; Elias, Laurence ; Treon, Steven P. ; Matsui, William ; Richardson, Paul ; Munshi, Nikhil C. ; Anderson, Kenneth C. / Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. In: Blood. 2012 ; Vol. 120, No. 9. pp. 1877-1887.
@article{76862cd3ac7d4946af412a689dc9329b,
title = "Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma",
abstract = "Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma (MM) growth within the BM microenvironment. PCI-32765 blocked RANKL/M-CSF - induced phosphorylation of Btk and downstream PLC-γ2 in OCs, resulting in diminished TRAP5b (ED50 = 17nM) and bone resorption activity. PCI-32765 also inhibited secretion of multiple cytokines and chemokines from OC and BM stromal cell cultures from both normal donors (ED50 = 0.5nM) and MM patients. It decreased SDF-1 - induced migration of MM cells, and down-regulated MIP1-α/CCL3 in MM cells. It also blocked MM cell growth and survival triggered by IL-6 or coculture with BM stromal cells or OCs in vitro. Importantly, PCI-32765 treatment significantly inhibits in vivo MM cell growth (P <.03) and MM cell-induced osteolysis of implanted human bone chips in SCID mice. Moreover, PCI-32765 prevents in vitro colony formation by stemlike cells from MM patients. Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM.",
author = "Tai, {Yu Tzu} and Chang, {Betty Y.} and Kong, {Sun Young} and Mariateresa Fulciniti and Guang Yang and Yolanda Calle and Yiguo Hu and Jianhong Lin and Zhao, {Jian Jun} and Antonia Cagnetta and Michele Cea and Sellitto, {Michael A.} and Zhong, {Mike Y.} and Qiuju Wang and Chirag Acharya and Carrasco, {Daniel R.} and Buggy, {Joseph J.} and Laurence Elias and Treon, {Steven P.} and William Matsui and Paul Richardson and Munshi, {Nikhil C.} and Anderson, {Kenneth C.}",
year = "2012",
month = "8",
day = "30",
doi = "10.1182/blood-2011-12-396853",
language = "English",
volume = "120",
pages = "1877--1887",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

AU - Tai, Yu Tzu

AU - Chang, Betty Y.

AU - Kong, Sun Young

AU - Fulciniti, Mariateresa

AU - Yang, Guang

AU - Calle, Yolanda

AU - Hu, Yiguo

AU - Lin, Jianhong

AU - Zhao, Jian Jun

AU - Cagnetta, Antonia

AU - Cea, Michele

AU - Sellitto, Michael A.

AU - Zhong, Mike Y.

AU - Wang, Qiuju

AU - Acharya, Chirag

AU - Carrasco, Daniel R.

AU - Buggy, Joseph J.

AU - Elias, Laurence

AU - Treon, Steven P.

AU - Matsui, William

AU - Richardson, Paul

AU - Munshi, Nikhil C.

AU - Anderson, Kenneth C.

PY - 2012/8/30

Y1 - 2012/8/30

N2 - Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma (MM) growth within the BM microenvironment. PCI-32765 blocked RANKL/M-CSF - induced phosphorylation of Btk and downstream PLC-γ2 in OCs, resulting in diminished TRAP5b (ED50 = 17nM) and bone resorption activity. PCI-32765 also inhibited secretion of multiple cytokines and chemokines from OC and BM stromal cell cultures from both normal donors (ED50 = 0.5nM) and MM patients. It decreased SDF-1 - induced migration of MM cells, and down-regulated MIP1-α/CCL3 in MM cells. It also blocked MM cell growth and survival triggered by IL-6 or coculture with BM stromal cells or OCs in vitro. Importantly, PCI-32765 treatment significantly inhibits in vivo MM cell growth (P <.03) and MM cell-induced osteolysis of implanted human bone chips in SCID mice. Moreover, PCI-32765 prevents in vitro colony formation by stemlike cells from MM patients. Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM.

AB - Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma (MM) growth within the BM microenvironment. PCI-32765 blocked RANKL/M-CSF - induced phosphorylation of Btk and downstream PLC-γ2 in OCs, resulting in diminished TRAP5b (ED50 = 17nM) and bone resorption activity. PCI-32765 also inhibited secretion of multiple cytokines and chemokines from OC and BM stromal cell cultures from both normal donors (ED50 = 0.5nM) and MM patients. It decreased SDF-1 - induced migration of MM cells, and down-regulated MIP1-α/CCL3 in MM cells. It also blocked MM cell growth and survival triggered by IL-6 or coculture with BM stromal cells or OCs in vitro. Importantly, PCI-32765 treatment significantly inhibits in vivo MM cell growth (P <.03) and MM cell-induced osteolysis of implanted human bone chips in SCID mice. Moreover, PCI-32765 prevents in vitro colony formation by stemlike cells from MM patients. Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM.

UR - http://www.scopus.com/inward/record.url?scp=84865585752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865585752&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-12-396853

DO - 10.1182/blood-2011-12-396853

M3 - Article

C2 - 22689860

AN - SCOPUS:84865585752

VL - 120

SP - 1877

EP - 1887

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -